| Literature DB >> 25151979 |
Heleen Dewitte1, Sandra Van Lint2, Carlo Heirman3, Kris Thielemans4, Stefaan C De Smedt5, Karine Breckpot6, Ine Lentacker7.
Abstract
Dendritic cell (DC)-based cancer vaccines, where the patient's own immune system is harnessed to target and destroy tumor tissue, have emerged as a potent therapeutic strategy. In the development of such DC vaccines, it is crucial to load the DCs with tumor antigens, and to simultaneously activate them to become more potent antigen-presenting cells. For this, we report on microbubbles, loaded with both antigen mRNA as well as immunomodulating TriMix mRNA, which can be used for the ultrasound-triggered transfection of DCs. In vivo experiments with in vitro sonoporated DCs show the effective induction of antigen-specific T cells, resulting in specific lysis of antigen-expressing cells. Especially in a therapeutic setting, sonoporation with TriMix has an important added value, resulting in a significant reduction of tumor outgrowth and a marked increase in overall survival. What is more, complete tumor regression was observed in 30% of the antigen+TriMix DC vaccinated animals, which also displayed long-term antigen-specific immunological memory. As a result, DC sonoporation using microbubbles loaded with a combination of antigen and TriMix mRNA can elicit powerful immune responses in vivo, and might serve as a potential tool for further in vivo DC vaccination applications.Entities:
Keywords: CFSE (PubChem CID: 16211581); Cancer vaccination; DOPE (PubChem CID: 9546757); DOTAP (PubChem CID: 6437371); Dendritic cell; Immune modulation; Microbubble; SIINFEKL (PubChem CID: 71311993); Sonoporation; mRNA
Mesh:
Substances:
Year: 2014 PMID: 25151979 DOI: 10.1016/j.jconrel.2014.08.011
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776